Genomic Evolution of Breast Cancer Metastasis and Relapse.

Cancer Cell 2017 08;32(2):169-184.e7

Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. Electronic address:

Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel of 365 genes on 299 samples from 170 patients with locally relapsed or metastatic breast cancer. Several lines of analysis indicate that clones seeding metastasis or relapse disseminate late from primary tumors, but continue to acquire mutations, mostly accessing the same mutational processes active in the primary tumor. Most distant metastases acquired driver mutations not seen in the primary tumor, drawing from a wider repertoire of cancer genes than early drivers. These include a number of clinically actionable alterations and mutations inactivating SWI-SNF and JAK2-STAT3 pathways.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.07.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559645PMC
August 2017
23 Reads

Publication Analysis

Top Keywords

breast cancer
16
metastatic breast
12
metastasis relapse
8
primary tumor
8
genomic evolution
8
cancer
5
tumors continue
4
acquire mutations
4
continue acquire
4
mutations accessing
4
mutational processes
4
active primary
4
processes active
4
primary tumors
4
accessing mutational
4
relapse disseminate
4
cancer lines
4
relapsed metastatic
4
locally relapsed
4
patients locally
4

Similar Publications

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Clin Cancer Res 2017 Aug 28;23(15):4402-4415. Epub 2017 Mar 28.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Paired primary breast cancers and metachronous metastases after adjuvant treatment are reported to differ in their clonal composition and genetic alterations, but it is unclear whether these differences stem from the selective pressures of the metastatic process, the systemic therapies, or both. We sought to define the repertoire of genetic alterations in breast cancer patients with metastatic disease who had not received local or systemic therapy. Up to two anatomically distinct core biopsies of primary breast cancers and synchronous distant metastases from nine patients who presented with metastatic disease were subjected to high-depth whole-exome sequencing. Read More

View Article
August 2017

PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.

Tumour Biol 2017 Jul;39(7):1010428317713492

4 Department of Interventional Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China.

Although the oncogenic role of PPFIA1 (liprin-α1) in breast cancer has been reported, whether its dysregulation is associated with metastasis risk or survival outcomes in breast cancer patients is not clear. Our primary data showed that PPFIA1 expression was significantly higher in liver metastatic breast tumors than in the primary tumors. Then, we tried to pool previous annotated genomic data to assess the prognostic value of PPFIA1 in distant metastasis-free survival, the risk of metastatic relapse, and metastatic relapse-free survival in breast cancer patients by data mining in two large databases, Kaplan-Meier plotter and bc-GenExMiner 4. Read More

View Article
July 2017

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Ann Oncol 2017 Nov;28(11):2866-2873

Foundation Medicine, Inc., Cambridge.

Background: Genomic changes that occur in breast cancer during the course of disease have been informed by sequencing of primary and metastatic tumor tissue. For patients with relapsed and metastatic disease, evolution of the breast cancer genome highlights the importance of using a recent sample for genomic profiling to guide clinical decision-making. Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative. Read More

View Article
November 2017

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Cancer 2016 09 10;122(17):2654-62. Epub 2016 Jun 10.

Foundation Medicine Inc, Cambridge, Massachusetts.

Background: Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)-targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified. Read More

View Article
September 2016